Pay in 4 interest-free payments of $5.79 Learn more
Ships within 48 hours · Estimated delivery Sep 22 - Sep 27
Key takeaways Animal studies show BPC-157 improves gastric motility and protects against gastric damage in rats No human clinical trial has tested BPC-157 for gastroparesis specifically BPC-157 modulates the nitric oxide system and may interact with vagal nerve function, both relevant to gastroparesis Oral administration (250-500 mcg daily) is preferred over injection for GI-targeted effects BPC-157 is unusually stable in stomach acid, making oral delivery viable Patients should work with their gastroenterologist before adding BPC-157 to their gastroparesis management What is gastroparesis and why is it hard to treat
10.1016/j.jmig.2007.06.003 136 YuL.SaileK.SwartzC
YJ: Data curation, Writing review and editing, Writing original draft, Methodology
Examples include: peptide therapy (at high doses or long-term use) TB-500 (Thymosin Beta-4) VEGF-mimetic peptides Tesamorelin/peptide therapy (via IGF-1 pathways) Potential risks of prolonged use: Scar tissue overdevelopment Feeding abnormal or cancerous cell growth Disrupting blood flow in sensitive tissues (eyes, kidneys) Thats why we recommend cycles like: TB-500 : 610 weeks on, 4+ weeks off peptide therapy injections : short-term, with oral BPC for maintenance Tesamorelin/peptide therapy : rotated or paused to avoid overexposure Other Peptides That Benefit From Cycling Even non-angiogenic peptides benefit from breaks: Thymosin Alpha-1 : 5-week cycles, 23x per year GHK-Cu : 78 week cycles, followed by rest Semax & Dihexa : pulsed use to maintain brain sensitivity 5-Amino-1MQ : cycled after 23 rounds for metabolic reset Each protocol is tailored to half-life, tissue targets, and sensitivity feedback
Esthe Anti-Mela Toning Cream A cream-serum hybrid ideal for sensitive and immediate post-procedure skin
